COSCIENS Biopharma Inc.

TSX:CSCI Stock Report

Market Cap: CA$12.3m

COSCIENS Biopharma Management

Management criteria checks 3/4

COSCIENS Biopharma's CEO is Gilles Gagnon, appointed in Jun 2024, has a tenure of less than a year. directly owns 1.15% of the company’s shares, worth CA$141.72K. The average tenure of the management team and the board of directors is 3.3 years and 0.5 years respectively.

Key information

Gilles Gagnon

Chief executive officer

US$133.5k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership1.2%
Management average tenure3.3yrs
Board average tenureless than a year

Recent management updates

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15
Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29
Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04
Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

CEO

Gilles Gagnon (70 yo)

less than a year

Tenure

US$133,500

Compensation

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Director of COSCIENS Biopharma Inc. (formerly known as Aeterna Zentaris Inc.) since June 03, 2024 and had been its Independent Director since January 1, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Gilles Gagnon
Presidentless than a yearUS$133.50k1.15%
CA$ 141.7k
Giuliano La Fratta
Senior VP of Finance & CFO2.9yrsUS$254.19kno data
Michael Teifel
Senior VP of Non-Clinical Development & Chief Scientific Officer3.6yrsUS$248.24kno data
Nicola Ammer
Chief Medical Officer & Senior VP of Clinical Development6.9yrsUS$212.55kno data
Matthias Gerlach
Senior Vice President Manufacturing and Supply Chain & Head of Productionno dataUS$263.11kno data

3.3yrs

Average Tenure

Experienced Management: CSCI's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gilles Gagnon
President4.9yrsUS$133.50k1.15%
CA$ 141.7k
Genevieve Foster
Independent Directorless than a yearno datano data
Gerald Batist
Member of the Scientific Advisory Boardno datano datano data
Hartmut Michel
Member of the Scientific Advisory Boardno datano datano data
Pierre Labbe
Directorless than a yearno datano data
Ronald Miller
Independent Chairmanno datano datano data
Marcel Verheij
Member of the Scientific Advisory Boardno datano datano data
René Frydman
Member of the Scientific Advisory Boardno datano datano data
Alan DeCherney
Member of the Scientific Advisory Boardno datano datano data
Klaus H. Diedrich
Member of the Scientific Advisory Boardno datano datano data
Frans M. Debruyne
Member of the Scientific Advisory Boardno datano datano data
Ulf Rapp
Member of the Scientific Advisory Boardno datano datano data

0.5yrs

Average Tenure

Experienced Board: CSCI's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 23:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

COSCIENS Biopharma Inc. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Douglas LoeCantor Fitzgerald Canada Corporation
Maher YaghiDesjardins Securities Inc.